TNF and rheumatoid arthritis: In the EULAR recommendations for rheumatoid arthritis (RA) the working group agreed on five general principles and eleven recommendations regarding the use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine) glucocorticoids (GC), biological (b) DMARDs (tumor necrosis factor inhibitors (TNFi) such as adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs (Janus kinase inhibitors such as tofacitinib, baricitinib, filgotinib, upadacitinib).